Skip to main contentSkip to navigationSkip to search
Curasight
  DKK  % |
Curasight

Interim report January – June 2021

August 24, 2021

Regulatory

Curasight A/S (“Curasight” or the “Company”) hereby publishes the interim report for the period January 1 – June 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight’s CEO Ulrich Krasilnikoff comments:

”During the quarter we successfully reported positive outcome of the biodistribution study in glioblastoma with uTREAT®, which constitutes a green light to proceed into further testing. Curasight’s uTREAT®-technology has previously shown promising results in completed preclinical studies in prostate and colorectal cancer. When complete data from the ongoing preclinical studies are available, they will serve as the first proof that our therapeutic technology is working. We look forward to continuing the study and reporting its results on a continuous basis.

Due to the encouraging results from the finalized clinical phase-II study in Prostate Cancer, Curasight will look into how to accelerate the product development and testing within Prostate Cancer, as we follow the plan but at a lower cost level than first anticipated. This means that Curasight is looking into how to further unfold the potential of uTRACE® for diagnosing and uTREAT® targeted radionuclide therapy in other cancer types where uPAR is also expressed.”

2

Q2 (2021-04-01 – 2021-06-30)

  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -404,869 (-152,386) DKK
  • Profit/loss before taxes amounted to -1,079,213 (-315,299) DKK
  • Profit/loss for the year amounted to -841,783 (-245,919) DKK
  • Total assets amounted to 60,860,495 (22,186,681) DKK
  • Equity ratio amounted to 94.4 (79.2)
  • Earnings per share amounted to -0.05 (-0.02)

Q1-Q2 (2021-01-01 – 2021-06-30)

  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -771,962 (-186,810) DKK
  • Profit/loss before taxes amounted to -2,076,728 (-563,364) DKK
  • Profit/loss for the year amounted to -1,619,848 (-439,424) DKK
  • Total assets amounted to 60,860,495 (22,186,681) DKK
  • Equity ratio amounted to 94.4 (79.2)
  • Earnings per share amounted to -0.09 (-0.03)

Highlights during the second quarter

  • On April 9, Curasight’s CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær presented the Company and its future plans, at the Nordnet Live platform.
  • On May 17, Curasight was awarded Best IPO in 2020 by the independent IPO Guide.
  • On June 1, Curasight held an Extraordinary General Meeting where Dr. Kirsten Drejer was elected as new member of the board of directors.
  • On June 18, Curasight announced that SEB will initiate commissioned research, meaning that SEB will continuously monitor and analyze Curasight’s operations, products, markets, and competitors.
  • On June 24, Curasight reported positive biodistribution data of uTREAT® in glioblastoma, which provides ”green light” to proceed with the next steps of development and testing.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.